APS more often overlaps with other systemic autoimmune diseases like systemic lupus erythematosus (SLE) or rheumatoid arthritis (RA) than occur as a distinct disease. Our purpose was to evaluate what are the differences between patients with primary APS and APS accompanying SLE. Objectives: The objective of this study was to compare patients with primary APS and APS/SLE group whther we can find find any clinical or laboratory parameters that can distinguish them from each other. Methods: 112 patients with APS were included to the study, 57 of them with primary APS and 55 with coexisting SLE. These patients were followed at the Department of Connective Tissue Diseases, NIGRiR, Warsaw, Poland. At inclusion a full medical history and physical examination data were recorded. Results: Both groups were similar in age, gender and duration of disease. Among all the clinical manifestations of APS, venous thrombosis was more frequent in patients with concomitant SLE. Skin involvement was significantly more prevalent in primary APS and it was caused mainly by livedo reticularis presence. From neurological manifestations, the occurrence of epilepsy was comparable, when EEG changes were more frequent in APS/SLE group. From laboratory measures, leucopenia, low complement concentrations and proteinuria were more prevalent in APS/SLE group. No differences were observed in thrombocytopenia and elongation of APTT as well as antiphospholipid antibody profile. Conclusions: In conclusion, arterial thrombosis is more characteristic for primary APS. We found that livedo reticularis is very characteristic feature for primary APS. Although epilepsy occurrence is comparable in APS and APS/SLE, higher frequency of EEG changes in APS/SLE group suggests that the mechanisms
damage. However, it is not yet well known whether hyperuricemia is independently associated with renal involvement even in patients without known predisposing factors for hyperuricemia such as decreased renal function, old age, male gender, menopause, and drugs. Objectives: The aim of this study was to evaluate the association of baseline serum uric acid level and development of nephritis in patients diagnosed with SLE. Methods: We retrospectively reviewed electronic medical records of 101 female SLE patients whose ages at the time of diagnosis (baseline) were 45 years old or below in a tertiary medical center from January 2000 to March 2015. SLE with renal involvement was diagnosed when patients met the renal disorder of the 1997 ACR criteria for SLE. We compared baseline serum uric acid levels of the SLE patients who had nephritis at the time of diagnosis or later (nephritis group) with the patients who had not developed nephritis (non-nephritis group) during follow-up period. Results: Among 101 patients, 22 (22%) had hyperuricemia (serum uric acid ≥6 mg/dL) at baseline and 45 (45%) had developed nephritis during follow-up period (median 6.1 years). There were significant differences in baseline serum uric acid level, glomerular filtration rate (GFR), anti-dsDNA antibody and complement level between non-nephritis group and nephritis group (Table) . Interestingly, among 59 patients with normal renal function (baseline GFR ≥90 mL/min/1.73m
2 ), baseline serum uric acid level was also significantly higher in the nephritis group than non-nephritis group (Table) . Moreover, the patients with hyperuricemia at baseline were more likely to develop nephritis than those without hyperuricemia during follow-up period (64% vs. 39%, p =0.042) (Figure) . Oxidative damage to nucleic acids has been found to be associated with etiopathogenesis and disease activity of inflammatory disorders. Oxidised guanine species have been recognized as a biomarker of oxidative DNA and RNA damage by endogenously generated oxygen radicals. Sjögren's syndrome (SS) is an autoimmune disorder and associated with overexpression of proinflammatory cytokines. Related to excess expression of proinflammatory cytokines, a prooxidant state could be postulated in SS. Objectives: We aimed to evaluate levels of nucleic acids oxidative stress products in patients with SS. Methods: 11 patients with SS diagnosed according to 2012 American College of Rheumatology (ACR) Classification Criteria for Sjögren's Syndrome, 19 patients with psoriatic arthritis (PsA), diagnosed according to Classification Criteria for Psoriatic Arthritis (PSARC), 9 patients with rheumatoid arthritis (RA), diagnosed according to 2010 Rheumatoid Arthritis Classification Criteria, and 12 healthy controls were included. All SS patients were on hydroxychloroquine sulphate 400mg/day. All PsA and RA patients were on methotrexate 15-20mg/week and folic acid 5 mg/week. The serum samples were collected from participants and stored at -30 C until assayed. Three oxidised guanine species, 8-hydroxy-2'-deoxyguanosine as a DNA oxidation marker, 8-hydroxyguanosine as a RNA oxidation marker, and 8-hydroxyguanine as a DNA and RNA oxidation marker, were measured using DNA/RNA Oxidative Damage ELISA Kit (Cayman Chemicals, USA). Statistics: All data are presented as mean and standard deviation (SD). Differences between groups were examined using Kruskal-Wallis tests. The Mann-Whitney U test was performed to test the significance of pairwise differences using Bonferroni correction to adjust for multiple comparisons. A p-value less than 0.05 were considered as statistically significant. Statistical analysis of correlation was performed by using the Spearman rank test. Results: There was no statistically significant difference between the groups in terms of age and gender. The average level of serum oxidised guanine species in the PsA, RA, SS and healthy control groups were 2871.77±336.20, 2672.20±292.04, 3375.57±344.21, 2777.55±237.05 pg/mL respectively. Oxidised guanine species levels were significantly higher in patients with SS and positively correlated with CRP levels (p:0.011, r: 0.726) ( Background: B lymphocyte stimulator factor (BLyS) is produced by wide range of cells of the immune system, and has proven to be a key factor in the selection and survival of B cells. BLyS is an important factor in the pathology of Systemic Lupus Erythematosus; elevated serum levels (≥20ng/mL) of soluble BlyS are at increased risk of flare. Objectives: Analyze the association among BLyS levels and clinical manifestations, as well as with SLE clinical activity. Methods: A cross-sectional and observational study was performed in patients diagnosed of SLE according to SLICC 2012 criteria and healthy controls. The study included a complete blood-test and clinical data collected by personal interview. Disease activity assessment was made by SLEDAI index and for the evaluation of chronic damage we used the validated SLICC damage index. Serum concentration of BLyS was analyzed by colorimetric methods. Lupus patients were dichotomized as high and low BLyS levels based on BLyS levels above 2 SD of the mean in healthy controls. Biostatistical analysis with R (3.3.2.) was performed.
Results: Two hundred forty-two SLE patients were evaluated; 94.4% of them were female. Mean values were as follow: age at diagnosis 33.29±13.53 years, disease duration 15.82±10.56 years, SLEDAI 5.91±5.06, SLICC score 1.06±1.42, BLyS levels 1.811±1.757 ng/mL. The 22.5% of patients displayed increased BLyS levels. The 29.6% of total patients exhibit SLEDAI values up to 6, and only the 7% of them showed SLEDAI values up to 6 and high BLyS levels simultaneously. Higher BLyS levels were significantly correlated to the ANAs positivity (p=0.0006) and lymphopenia (p=0.01) but showed no correlation with hypocomplementemia neither anti-dsDNA. The statistical analysis did not yield differences in the clinical activity or accumulated damage between patients with lower and higher BLyS levels. Conclusions: In our series we observed a 22.5% of patients with high levels of BLyS, and the 7% of cases had BLyS high levels and SLEDAI>6. BLyS upregulation is related to ANAs positivity and lymphopenia. We have found no statistical evidences on the relationship of BLyS levels and clinical activity in our series of patients. Conclusions: The 69% of our SLE patients displayed almost one cytokine increased, being the INF1A the cytokine that mainly is increased. However, increased IL10 levels, irrespective of whether there is also increased levels of BLyS and/or INF1A, is the cytokine which best fits to clinical activity in SLE. Background: Survival of systemic lupus erythematosus (SLE) patients has improved dramatically due to improved treatment, and the morbidity pattern has shifted towards long-term complications as osteoporosis. SLE occurs in women during child-bearing years and the disease often persists to the postmenopausal period 1 . Assessment of fracture risk in SLE patients is important as fractures may occur while bone mineral density (BMD) is above the osteoporotic threshold or at the normal range 2 . Osteocalcin measurement helps to assess fracture risk and select patients for treatment. Objectives: To assess the fracture risk in a cohort of Egyptian female SLE patients by using BMD and osteocalcin level with correlation to disease activity, damage index and drugs in use. Methods: 70 females with SLE ≥40 years old satisfying the SLICC classification criteria were enrolled with detailed history taking including disease duration, drugs in use, traditional risk factors, regular exercise, history of previous fractures and menstrual history. Assessment of disease activity using Systemic Lupus Erythematosus Disease Activity Index (SLEDAI) and disease damage using the Systemic Lupus International Collaborative Clinics/ American College of Rheumatology Damage Index (SLICC/ACR DI). Serum calcium, phosphorus and alkaline phosphatise were measured. BMD measured by dual energy X-ray absorpiometry (DEXA) scans at lumbar spine (LS) (L2-L4) and femoral neck (FN), serum osteocalcin level and World Health Organization fracture risk assessment tool (FRAX ® ). Results: 14//70 (20%) patients had LS osteoporosis, 25//70 (35.7%) had LS osteopenia and 6/70 (8.6%) had FN osteoporosis, 30/70 (42.9%) had FN osteopenia. FRAX-Major ≥20% was observed in 10% of patients, FRAX-HIP ≥3% was seen in 27.1% of patients. Serum osteocalcin level was significantly decreased in SLE patients with lower BMD than those with normal BMD, and significantly decreased in patients with osteoporosis than those with osteopenia. A significant negative correlation was found between osteocalcin level and age of patients, disease duration, SLEDAI and SLICC scores, current, IV pulse and cumulative steroids, immunosuppressants, anticoagulants, but there was a positive correlation with antimalarials and calcium supplements. Conclusions: SLE patients are at greater risk for developing osteoporosis and osteopenia. Ten-year risk of major and hip fractures was high in SLE patients. Increasing age, disease duration, high anti-DNA titres, SLEDAI and SLICC were associated with a higher 10-year probability of major osteoporotic fracture. FRAX predicted incident hip and major osteoporotic fractures among SLE patients with normal and low bone mass not just those with frank osteoporosis. Physicians should be alerted to the higher risk of future fractures in SLE patients for periodic monitoring. 
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